Paris based Coave Therapeutics is conjugating ligands onto vector surfaces to improve targeting and delivery - it is attracting partner and investor interest

blonca9
Sep 5, 2024
1 min read

CEO Rodolphe Clerval describes the scientific rationale, and how Coave has engineered this to be easy to add at the end of vector manufacturing. Plus, he shares an update on the company's fundraising, partnering, and wholly owned programs.

Recent Posts

See All

AI News: Singapore based Gero, a company focused on small molecules for aging conditions, launched ProtoBind-Diff, a model using amino acid sequences rather than structure models for discovery

ArsenalBio's Co-Founder & CEO Ken Drazan talks about engineering the next generation of T-cell therapies, including a clinical stage renal cell program that includes multiple features

Checking in with the co-founders of Amylyx Pharmaceuticals, which now has one program in pivotal, another that may start soon, and earlier stage clinical programs that will have data this year

Paris based Coave Therapeutics is conjugating ligands onto vector surfaces to improve targeting and delivery - it is attracting partner and investor interest

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight